Published in Hum Vaccin Immunother on December 17, 2013
Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. AIDS Res Hum Retroviruses (2014) 0.79
Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines (Basel) (2017) 0.76
Preparation and characterization of novel chitosan-protamine nanoparticles for nucleus-targeted anticancer drug delivery. Int J Nanomedicine (2016) 0.75
Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems. Hum Vaccin Immunother (2016) 0.75
Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually. Vaccine (2015) 0.75
Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. Int J Adv Res (Indore) (2016) 0.75
Current prospects and future challenges for nasal vaccine delivery. Hum Vaccin Immunother (2016) 0.75
Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice. J Leukoc Biol (2017) 0.75
Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination. Virol J (2016) 0.75
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med (2004) 4.10
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis (2010) 2.64
Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev (2009) 2.11
Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol (2000) 2.06
Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev (2001) 1.87
Adjuvants--a balance between toxicity and adjuvanticity. Vaccine (1993) 1.86
The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol (2009) 1.67
The cost of unsafe injections. Bull World Health Organ (1999) 1.60
A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine (2002) 1.58
Vaccine adjuvants: current challenges and future approaches. J Pharm Sci (2009) 1.50
Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol J (2009) 1.39
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol (2000) 1.32
Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci (1997) 1.28
Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev (2009) 1.26
Mucosal vaccine adjuvants update. Clin Exp Vaccine Res (2012) 1.15
Polysaccharide drug delivery systems based on pectin and chitosan. Biotechnol Genet Eng Rev (2010) 1.13
Effective nasal influenza vaccine delivery using chitosan. Vaccine (2005) 1.09
Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release (2012) 1.03
Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun (2003) 1.03
Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines (2009) 0.99
Interaction of bile acids, phospholipids, cholesterol and triglyceride with dietary fibers in the small intestine of rats. J Nutr (1989) 0.95
Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv (2012) 0.94
Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis (1998) 0.93
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials (2010) 0.93
The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccin Immunother (2012) 0.91
Nasal drug delivery - recent developments and future prospects. J Control Release (2012) 0.87
Is glucosamine safe in patients with seafood allergy? J Allergy Clin Immunol (2004) 0.85
Nasal vaccine innovation. J Drug Target (2010) 0.83
Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLoS One (2014) 0.82
Safety of chitosan bandages in shellfish allergic patients. Mil Med (2011) 0.81
Do shrimp-allergic individuals tolerate shrimp-derived glucosamine? Clin Exp Allergy (2006) 0.79
The analgesic efficacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model. Anesth Analg (2008) 0.78
Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med (2008) 0.77
Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. Br J Clin Pharmacol (1999) 0.76